Sana Biotechnology, Inc. cash flow to debt ratio of -182.38% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Sana Biotechnology, Inc.'s free cash flow has increased -43.58% from $-256.58M last year to $-144.77M, signaling increasing performance

Sana Biotechnology, Inc.'s debt to equity ratio is 0.48, which means that the company's assets are healthy financed, signaling financial stability.

Sana Biotechnology, Inc.'s debt has increased relative to shareholder equity from 0.38 last year to 0.48 today, signaling weakened financials

Sana Biotechnology, Inc. has a net cash position, so leverage is healthy.

Sana Biotechnology, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Sana Biotechnology, Inc. has insufficient data to evaluate this check.

Sana Biotechnology, Inc.'s short-term assets of $148.68M exceed its short-term liabilities of $78.73M

Sana Biotechnology, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Sana Biotechnology, Inc.'s return on equity of -134.49%, is lower than 15.00%, indicating bad performance

Sana Biotechnology, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Sana Biotechnology, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Sana Biotechnology, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Sana Biotechnology, Inc. has negative free cash flow, indicating cash burn

Sana Biotechnology, Inc.'s yearly earnings has increased -8.47% since last year from $-266.76M to $-244.17M, signaling increasing performance

Sana Biotechnology, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -64.54% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Sana Biotechnology, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Sana Biotechnology, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Sana Biotechnology, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Sana Biotechnology, Inc. has insufficient data to evaluate this check.

Sana Biotechnology, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Sana Biotechnology, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Sana Biotechnology, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Sana Biotechnology, Inc. has insufficient data to evaluate this check.

Sana Biotechnology, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Sana Biotechnology, Inc. has a price-to-book ratio of 6.91x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Sana Biotechnology, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue